GliaCure is focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets. GliaCure was founded in 2011 and is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University. Professor Haydon has partnered with Michael Szulczewski, who successfully co-founded the imaging company Prairie Technologies, Inc. Their complementary skills in academia and industry provide a solid basis for success in this new venture.
GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery…more »
26
Apr
GliaCure President Phil Haydon’s research on Alzheimer’s disease is featured in Tufts Now, the online content and information hub for the university community. The article, authored by Bruce Morgan, details the initial resistance by the scientific community to the hypothesis that glia play an active role in brain signaling, Phil’s first discoveries regarding the role...more »